NewsBytes reports that Lilly's experimental triple-hormone drug lowered the number of sleep apnea episodes in study participants. Tap through for the trial details.
Recap by typeshit. Full story at NewsBytes.
Half of people with diabetes for 10 years or more said they were very satisfied on a GLP-1. Gen Z users were the most likely to stop and restart treatment.
64% of current users faced some negative reaction. Men, BIPOC respondents and the newly diagnosed reported it most, while 69% of boomers felt none.
The workflow uses glutathione or sulfatase triggers to target organelles and tumors in mice, and the authors say it takes 92 to 115 days to run.
A University of Pennsylvania mouse study found on-off GLP-1 use left mice 20 per cent heavier than those kept on the drug, and doctors warn human effects are unknown.
The think tank argues regulated compounding beats 'research use only' sellers, noting an FDA panel voted to add six peptides despite staff advising against all seven.
NSW peptide hospitalisations went from five in July 2025 to over 200 in September 2026, and needle programs say syringe machines are emptying within hours.
Loading…